恒瑞医药：拟用于治疗前列腺癌的HRS-5041获批开展临床试验

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for the clinical trial of HRS-5041, a new selective AR-PROTAC small molecule aimed at treating prostate cancer [1] Company Summary - HRS-5041 is designed to effectively degrade both wild-type and various mutant AR proteins, showing potential to overcome resistance compared to second-generation AR inhibitors [1] - The total research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally, indicating a unique position for HRS-5041 in the market [1]